Therapixel, a pioneer in medical imaging AI, announced that it will showcase its award-winning breast imaging solution MammoScreen at the Radiological Society of North America (RSNA) 2025 Annual Meeting in Chicago. Attendees can visit Booth #5144 to experience live demos, meet product leaders and practicing radiologists, and see firsthand how MammoScreen is helping radiologists read smarter, faster, and with greater confidence.
MammoScreen is an FDA-cleared AI decision-support tool designed to assist radiologists in interpreting 2D and 3D mammograms. It analyzes current and prior images simultaneously, helping streamline workflows, enhance diagnostic accuracy, and reduce fatigue. Developed from the Dream Challenge-winning algorithm – the world’s largest breast imaging AI competition – MammoScreen continues to set the standard for innovation in AI-assisted breast screening.
“At Therapixel, we’ve focused on building technology that truly complements the expertise of radiologists,” said Matthieu Leclerc Chalvet, CEO of Therapixel. “MammoScreen empowers clinicians to make confident decisions faster, improving both efficiency and patient outcomes. RSNA is an opportunity for us to demonstrate just how powerful this collaboration between human insight and AI can be.”
MammoScreen’s unique red-yellow-green scoring system provides instant visual feedback on the likelihood of malignancy, allowing radiologists to quickly and confidently review cases. Its unique pre-reporting integration enables seamless report generation within existing systems—saving valuable time without disrupting clinical workflows.
Studies have shown that MammoScreen helps radiologists improve both performance and reading experience:
- 100% of users have reported measurable improvements in accuracy.
- 83% report reduced fatigue and greater reading confidence.
- 97% agreement rate between MammoScreen suspicious cases and radiologist recall decisions.
At RSNA 2025, attendees will have the chance to:
- See live demos of MammoScreen in action, including how it analyzes 2D, 3D, and prior exams simultaneously.
- Participate in “office hours” sessions with leading radiologists who use MammoScreen in clinical practice.
- Speak directly with Therapixel’s CEO, Chief Product Officer, and Founder about the technology’s development, clinical validation, and integration into real-world workflows.
Visitors can also take part in an interactive MammoScreen challenge at the booth – testing their own screening intuition against the AI.
“As a radiologist, the difference MammoScreen makes is immediately clear,” said Svati Singla Long, MD, a practicing breast radiologist who uses the solution in daily workflow. “It helps streamline our assessments, reduces fatigue, and allows us to take care of our patients with an added boost of confidence.”
MammoScreen is trusted by leading imaging practices across the U.S., including Onsite Women’s Health, SimonMed and Hoag Hospital. It is also used by major academic institutions, including Mayo Clinic.
Therapixel’s team will be available throughout the RSNA conference to provide demonstrations, answer questions, and share insight into the company’s continued innovation in AI-driven breast imaging.
